Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | Director | June 21, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date June 21, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2036-06-20 | Direct | 4,200 |
Reported balance
After 2026-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-21 · Grant · Acquired 4,200 · Balance 4,200 F1: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2026 Filed Jun 23, 2026 20:31 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 4,200 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001265123-26-000001 · ownership.xml · derivative · entry 1 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,200 Underlying: Common Stock · 4,200 shares Expires 2036-06-20 F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0000950170-25-086160 · ownership.xml · derivative · entry 2 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2035-06-10 F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086160 · ownership.xml · nonDerivative · entry 1 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,700 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0000950170-24-100174 · ownership.xml · derivative · entry 8 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0000950170-24-100174 · ownership.xml · derivative · entry 7 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0000950170-24-100174 · ownership.xml · derivative · entry 6 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0000950170-24-100174 · ownership.xml · derivative · entry 5 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $15.93 | $0.00 |
DisclosureSEC source: 0000950170-24-100174 · ownership.xml · derivative · entry 4 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-04-29 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0000950170-24-100174 · ownership.xml · derivative · entry 3 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires 2031-04-29 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0000950170-24-100174 · ownership.xml · derivative · entry 2 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-09-16 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0000950170-24-100174 · ownership.xml · derivative · entry 1 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2030-09-16 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:05 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0000950170-24-070608 · ownership.xml · derivative · entry 2 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2034-06-04 F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:05 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070608 · ownership.xml · nonDerivative · entry 1 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,800 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046094 · doc4.xml · derivative · entry 8 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001209191-23-046094 · doc4.xml · derivative · entry 7 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046094 · doc4.xml · derivative · entry 6 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0001209191-23-046094 · doc4.xml · derivative · entry 5 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046094 · doc4.xml · derivative · entry 4 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-04-29 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $15.93 | $0.00 |
DisclosureSEC source: 0001209191-23-046094 · doc4.xml · derivative · entry 3 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires 2031-04-29 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046094 · doc4.xml · derivative · entry 2 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-09-16 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on September 17, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0001209191-23-046094 · doc4.xml · derivative · entry 1 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2030-09-16 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on September 17, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 20:08 UTC | Adicet Bio, Inc. ACET · Entity 6860 | PurchaseCommon Stock | 5,000 | $2.40 | $11,999.50 |
DisclosureSEC source: 0001209191-23-040299 · doc4.xml · nonDerivative · entry 1 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,900 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $2.3997 to $2.3999, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the Securities and Exchange Commission staff upon request. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 21:47 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001209191-23-033956 · doc4.xml · derivative · entry 2 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 21:47 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033956 · doc4.xml · nonDerivative · entry 1 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,900 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:36 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0001209191-22-034079 · doc4.xml · derivative · entry 1 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common stock · 18,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:23 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $15.93 | $0.00 |
DisclosureSEC source: 0001209191-21-030097 · doc4.xml · derivative · entry 1 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-04-29 F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:56 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0000899243-20-025655 · doc4.xml · derivative · entry 1 DUBIN STEVE · CIK 0001265123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-09-16 F1 · derivative.exercise_date: This option shall vest as follows: 1/36th of the shares shall vest on each of the next thirty-six (36) monthly anniversaries of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.